Comprehensive medication guide to SARS-CoV-2 Treatment including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$75 copay for Paxlovid with commercial insurance; Tier 2–3 on most Part D plans; Medicare Part D is required to cover oral COVID-19 antivirals. The 2026 Part D annual out-of-pocket cap is $2,100. Prior authorization increasingly required on ACA marketplace plans.
Estimated Cash Pricing
$1,390–$1,820 retail for Paxlovid per 5-day course without assistance; as low as $0 for eligible patients through Pfizer's PAXCESS program (paxlovid.com) or $0 with PAXCESS co-pay card for commercially insured patients.
Medfinder Findability Score
55/100
On this page
SARS-CoV-2 antiviral medications are prescription drugs designed to fight the virus that causes COVID-19. They work by directly targeting viral replication — stopping the virus from making copies of itself inside your body. Unlike COVID-19 vaccines, which prevent infection, antivirals treat active infection after a positive test and must be started within five days of symptom onset to be effective.
The primary antiviral medications available in 2026 include Paxlovid (nirmatrelvir/ritonavir) by Pfizer — the first-line oral option — as well as Veklury (remdesivir) by Gilead Sciences, available as an IV infusion. Xocova (ensitrelvir) by Shionogi received FDA approval in June 2026 for post-exposure prophylaxis.
These medications are indicated for patients at high risk of progressing to severe COVID-19, including older adults (50+), people with diabetes, heart disease, obesity, chronic lung disease, kidney disease, and immunocompromised individuals. Per clinical trial data, Paxlovid reduced the risk of hospitalization or death by approximately 89% in high-risk, unvaccinated adults when started within three days of symptom onset.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Paxlovid's active antiviral component, nirmatrelvir, works by inhibiting the SARS-CoV-2 main protease (Mpro) — an enzyme the virus requires to cleave a large polyprotein precursor into the functional proteins needed to assemble new viral particles. By blocking Mpro, nirmatrelvir prevents the virus from producing the components it needs to replicate. Ritonavir, the second component, is not itself an antiviral; it inhibits the CYP3A4 liver enzyme that would otherwise rapidly break down nirmatrelvir, allowing effective antiviral concentrations to be maintained throughout the 5-day course.
Remdesivir (Veklury) uses a different approach: as a nucleotide analog, it mimics a building block of viral RNA. When the virus's RNA polymerase enzyme incorporates remdesivir instead of the real nucleotide during genome copying, the polymerase stalls, producing incomplete and non-infectious viral copies. Xocova (ensitrelvir) also targets the SARS-CoV-2 main protease, but unlike Paxlovid, it doesn't require ritonavir boosting, resulting in significantly fewer drug interactions.
All COVID-19 antivirals are most effective when started early — within the first three days of symptoms — because they work by stopping ongoing viral replication. By five days after symptom onset, viral load is often already declining, reducing the window of maximum benefit.
Nirmatrelvir 300 mg / Ritonavir 100 mg — tablet (oral, co-packaged)
Standard Paxlovid dose: 2 nirmatrelvir 150mg tablets + 1 ritonavir 100mg tablet twice daily × 5 days. For normal renal function or mild impairment.
Nirmatrelvir 150 mg / Ritonavir 100 mg — tablet (oral, renal dose pack)
Paxlovid renal dose pack: 1 nirmatrelvir 150mg tablet + 1 ritonavir 100mg tablet twice daily × 5 days. For moderate renal impairment (eGFR 30–59 mL/min).
200 mg / 100 mg — intravenous solution (Remdesivir/Veklury)
Remdesivir outpatient: 200mg IV on Day 1, then 100mg IV once daily on Days 2–3. Administered at infusion center.
As prescribed — tablet (oral, Xocova/ensitrelvir)
Xocova (ensitrelvir): dosing per FDA-approved labeling for post-exposure prophylaxis. Approved June 2026.
As of 2026, Paxlovid is not on the FDA's official drug shortage list — national supply from Pfizer is adequate. However, pharmacy-level stockouts occur frequently during seasonal COVID-19 surges. Many pharmacies don't routinely stock Paxlovid due to its high wholesale cost ($1,400–$1,600 per course) and the risk of expiration if demand is unpredictable. Large chain pharmacies (CVS, Walgreens, Walmart) generally maintain inventory but can sell out within days during winter waves. Hospital outpatient pharmacies tend to be the most reliable source.
Rural and underserved communities face additional challenges, with fewer pharmacies overall and less consistent stocking. The renal dose pack (nirmatrelvir 150/ritonavir 100 mg) is less commonly stocked than the standard pack, making it harder to find for patients with moderate kidney impairment.
When your pharmacy is out, medfinder can help you locate a pharmacy with COVID-19 antivirals in stock. medfinder calls pharmacies near you and texts you the results — saving you hours of phone calls while you're sick and the treatment clock is ticking.
COVID-19 antivirals (Paxlovid, Remdesivir, Xocova) are not controlled substances and carry no DEA scheduling restrictions. Any licensed prescriber in all 50 states can prescribe these medications. Because Paxlovid requires a thorough drug interaction screen before prescribing, providers with access to your complete medication history — your primary care physician or pharmacist — are particularly well-positioned to prescribe efficiently.
Prescriber types who commonly prescribe COVID-19 antivirals:
Telehealth platforms offer same-day COVID-19 consultations with Paxlovid prescriptions on most major services. This is often the fastest route when your primary care physician is unavailable, especially on evenings, weekends, and holidays. Many telehealth platforms also have insight into local pharmacy availability and can route prescriptions to pharmacies with confirmed stock.
No. Paxlovid (nirmatrelvir/ritonavir), Remdesivir (Veklury), and Xocova (ensitrelvir) are not controlled substances. They are not scheduled by the DEA and do not carry the prescribing restrictions associated with controlled medications like opioids or stimulants.
This means any licensed prescriber — including nurse practitioners, physician assistants, primary care physicians, urgent care providers, and telehealth providers — can prescribe these medications without a DEA registration number or special DEA Schedule II exemptions. It also means the medications can be prescribed via telehealth without additional restrictions. However, they do require a valid prescription and are not available over the counter.
Paxlovid (nirmatrelvir/ritonavir) common side effects:
Serious side effects — seek immediate medical care if you experience:
Know what you need? Skip the search.
Remdesivir (Veklury)
FDA-approved IV antiviral; 3-day outpatient infusion course; fewer drug interactions than Paxlovid; requires infusion center access; strong evidence base. ~$2,000–$3,000 without assistance.
Xocova (Ensitrelvir)
FDA-approved June 2026 for COVID-19 post-exposure prophylaxis; SARS-CoV-2 main protease inhibitor; significantly fewer drug interactions than Paxlovid as it doesn't require ritonavir boosting. Newer, still building distribution.
Molnupiravir (Lagevrio)
Oral antiviral under EUA; ~30% reduction in hospitalization (less effective than Paxlovid's ~89%); fewer drug interactions; limited commercial availability in 2026 after government supplies expired.
Supportive Care
Rest, hydration, acetaminophen/ibuprofen for fever. Appropriate for low-risk, healthy, vaccinated adults with mild COVID-19 and estimated hospitalization risk ≤0.5% per IDSA guidelines.
Prefer SARS-CoV-2 Treatment? We can find it.
Rifampin (Rifampicin)
majorStrong CYP3A inducer — contraindicated; may render Paxlovid ineffective by dramatically reducing nirmatrelvir concentrations. Do not take within 2 weeks of Paxlovid.
St. John's Wort
majorHerbal CYP3A inducer — contraindicated with Paxlovid; reduces nirmatrelvir blood levels, potentially rendering treatment ineffective.
Amiodarone / Dronedarone
majorAntiarrhythmics — contraindicated; ritonavir increases blood levels, risking serious cardiac arrhythmias.
Tacrolimus / Cyclosporine (Calcineurin Inhibitors)
majorBlood levels can spike dramatically with ritonavir's CYP3A4 inhibition — potentially causing nephrotoxicity or other serious effects. Most transplant patients should use Remdesivir instead.
Lovastatin / Simvastatin
majorContraindicated — risk of severe myopathy and rhabdomyolysis when statin blood levels are dramatically elevated by ritonavir. Hold for duration of treatment plus 2-3 days after.
Warfarin (Coumadin)
moderateINR can increase significantly; monitor INR during and 2-3 days after Paxlovid treatment. Adjust warfarin dose as needed.
Calcium Channel Blockers (Amlodipine, Diltiazem, Verapamil)
moderateBlood levels increase due to CYP3A4 inhibition; may need dose adjustment and blood pressure monitoring.
Colchicine
moderateBlood levels increase significantly; potentially toxic. Temporarily hold colchicine during Paxlovid treatment.
COVID-19 antiviral treatment in 2026 is more effective, better covered by insurance, and more financially accessible than most patients realize. Paxlovid reduced hospitalization and death by approximately 89% in high-risk patients in clinical trials — a dramatic benefit that makes early treatment one of the most impactful interventions available for COVID-positive high-risk individuals. Remdesivir and Xocova offer meaningful alternatives for patients with drug interactions or other contraindications.
The biggest practical challenges in 2026 are pharmacy availability (stockouts during seasonal surges) and cost (the retail price of $1,390–$1,820 deters many uninsured patients). Both are solvable: Pfizer's PAXCESS program provides Paxlovid at no cost to eligible uninsured and Medicare/Medicaid patients through December 2026, and the PAXCESS co-pay card covers commercially insured patients. The key is knowing these programs exist and enrolling quickly.
If you've tested positive for COVID-19 and been prescribed an antiviral, act immediately — contact your provider, check your assistance program eligibility, and use medfinder to locate a pharmacy with stock near you. The five-day window is short, but with the right tools, most patients can get treated within it.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
Real-time availability
Medfinder is actively checking pharmacy inventory for SARS-CoV-2 Treatment. We don't publish a number until we have enough verified pharmacy checks to be accurate — start a search and our team confirms current availability near you, usually within 24 hours.
ChatGPT
Claude
Gemini
